AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 111 min read$RMD

Farrell Michael J. sold $1.0M of RMD

Farrell Michael J. (Chairman and CEO) sold 4,991 shares of RESMED INC (RMD) at $205.69 ($1.03M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farrell Michael J.
Published Aug 11, 2026, 10:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 10:38 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RMD
Neutral
high confidence
Mentioned
$RMD
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDNeutralLow
01

Why it matters

The only new fact is the reported sale size, price, and post-transaction holdings, with no accompanying guidance, earnings, or business update.

02

Market read

Traders may note the sale for sentiment, but the 10b5-1 structure and lack of fundamental updates make it low signal.

03

What to watch

10b5-1 plans are designed to reduce timing-based signaling; the filing does not disclose reasons for the sale or any change in company outlook.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11, transaction dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for ResMed (RMD).

Company-level read

Ticker impact

$RMDNeutralHigh confidence
Context

ResMed disclosed that Chairman and CEO Michael J. Farrell sold 4,991 shares at $205.6895 on 2026-08-07 under a 10b5-1 plan.

Expected impact

Likely minimal impact; any reaction is typically short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operational, financial, or regulatory information about ResMed.

Market effects

Sector

No clear sector read-through from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can still be interpreted as confidence-neutral or tax-driven, but traders may overreact if they treat 10b5-1 as discretionary.

Key entities

  • issuer
    ResMed Inc

    Company whose insider transaction was reported on Form 4.

  • insider
    Farrell Michael J.

    Chairman and CEO who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RMD insider trading history →

Related articles

AUG 15
$RMDMed

Why You Should Consider Buying ResMed Stock After Its First-Ever Annual Guide

ResMed (RMD) issued its first full annual guidance for FY27, targeting $5.75B to $5.85B revenue and non-GAAP EPS of $12.00 to $12.25, with 5% to 7% core constant-currency revenue growth and 12% to 14% core EPS growth after an Astral ventilator sales suspension. Q4 results included $1.5B revenue and $2.95 non-GAAP EPS. Analysts’ mean target is $247.20 vs. $224.46 close.

tikr.com6 min
AUG 12
$RMDMed

ResMed: Shareholder Returns Target More Than $1.85 Billion After Free Cash Flow Reaches $1.65 Billion

ResMed said it expects to generate $1.65 billion in free cash flow in fiscal 2026 and return more than $1.85 billion to shareholders via dividends and buybacks in fiscal 2027. In fiscal 2026, revenue rose 10% to $5.65 billion, non-GAAP diluted EPS rose 17% to $11.17, and the quarterly dividend increased 10% to $0.66. Q4 revenue was about $1.46 billion. ResMed also agreed to sell MatrixCare and completed the Noctrix Health acquisition.

pulse2.com3 min
AUG 10
$RMDMedAI 8/10

Resmed’s stock falls by 7% on soft FY27 outlook

ResMed shares fell about 7% after the company forecast softer FY27 revenue due to suspended Astral ventilator sales, macro uncertainty, and inflation in electronic components and freight. ResMed reported FY26 revenue of about $5.65bn (+10% YoY) and Q4 revenue of $1.46bn (+9%). FY27 revenue guidance is $5.75bn to $5.85bn, below analysts’ $5.92bn, citing a $75m headwind from an FDA Class 1 recall.

yahoo.com4 min
AUG 9
$RMDMed

Off Into Weekend, As Early Work Undone

ResMed (ASX:RMD) fell 8.29% on Friday and is 3.09% lower for the week after a strong run. The company reported a solid Q4, with FY26 revenue up 10% to $5.7b, gross Q4 margin 62.3%, FY EPS up 17% to $11.17, and a 10% dividend increase to $0.66. Morgan Stanley downgraded to Equal Weight and cut its price target, citing cooling growth and Philips’ potential US return in 2027.

thebull.com.au6 min
AUG 9
$RMDHighAI 9/10

ResMed Q4 Earnings Call Highlights

ResMed (NYSE:RMD) reported Q4 non-GAAP gross margin up 90 bps to 62.3% YoY, citing productivity and supply-chain efficiency, but down ~50 bps sequentially due to higher component and freight costs and a ~20-bp FX headwind. The company set a $42M Astral field safety provision and guided FY2027 reported revenue $5.75B-$5.85B and non-GAAP EPS $12.00-$12.25, plus $1.5B buybacks and a 10% dividend increase.

finance.yahoo.com6 min